<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230414057904N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-01-10</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of maintenance serum with the amount of sodium at the limit of isotonic saline on sodium level, blood pressure and acidosis in admitted patients.</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of maintenance serum with the amount of sodium at the limit of isotonic saline on sodium level, blood pressure and acidosis in PICU patients of Tehran Bahrami Children's Hospital</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-03-25</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/69624</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are assigned to normal and half-saline groups, one by one, and based on the Block Random Allocation software with variable sizes multiples of 2. Randomization in two strata will be done separately. We write every code on paper and put it in a pocket which its content cannot be read. Every code is allocated to every patient who is included until the end, Blinding description: The legal guardian and/or the patient is aware of participating in the study but, does not know the fluid types. The care provider and the nurse who are not a research member know the fluid type but, the investigator, outcome assessor, and data analyzer do not.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Hypertension. Condition 2: Influence of the maintenance fluid (normal vs. half saline) on blood sodium level.</hc_freetext>
      <i_freetext>Intervention 1: Normal saline maintenance fluid, 4cc/kg.h for first 10kg, 2cc/kg.h for second 10kg, and 2cc/kg.h for third and more 10kg. There is no specific brand to use and it will depend on Bahrami hospital's drugstore. Training sessions is not in our method. Administration time will depend on ICU admission period. The chemical formula is obvious according to drug's name and it is NaCl 0.9%. Intervention 2: Control group: Half saline maintenance fluid, 4cc/kg.h for first 10kg, 2cc/kg.h for second 10kg, and 2cc/kg.h for third and more 10kg. There is no specific brand to use and it will depend on Bahrami hospital's drugstore. Training sessions is not in our method. Administration time will depend on ICU admission period. The chemical formula is obvious according to drug's name and it is NaCl 0.45%.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The information related to the questionnaire, which includes the individual characteristics of the participants and the variables and outcomes, will be shared.

When:
The access period starts from 1402

To whom:
Study documents will be accessible to study reviewers and researchers of academic and scientific centers.بر

Conditions:
The study documents will be accessible to the reviewers of the project for the purpose of verification without conditions. It will be useful for others (researchers working in academic and scientific institutions) in order to improve the quality of treatment in childrens fild with respect to trustworthiness standards.

Where to obtain:
Applicants can request the study documents from the researcher through the postal address and e-mail, and they can also interact in person.

Email : faezehjahanshahi3@gmail.com
Postal code : 1955673933
 Address : No. 29,. Sabouri St,. Alborz St., Naft Town,. Artesh Sharq Highway., Imam Ali Highway., Tehran

How to obtain:
The study documents will be sent to the email address after the request which should be from an ethical committee or reference and with the supervisor professor's permission.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Faezeh Jahanshahi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 29, Alborz St., Sabouri St., Naft Town, Imam Ali Hwy</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1955673933</zip>
        <telephone>+98 21 2244 2920</telephone>
        <email>faezehjahanshahi@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Faezeh Jahanshahi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 29 , Shahid Saburi Ave , Alborz Ave , Abadan Blvd , Naft Town , Artesh Shargh Highway , Emam Ali Highway</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1955673933</zip>
        <telephone>+98 21 2244 2920</telephone>
        <email>faezehjahanshahi3@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 3 months and 18 years
Need for injectable serum</inclusion_criteria>
      <agemin>3 months</agemin>
      <agemax>18 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Sodium level below 130 mmol/L
Sodium level above 150 mmol/L
Having diabetes insipidus
Diabetic ketoacidosis
Kidney disease requiring dialysis
Suffering from the disease of high sodium urinary excretion(Addison's disease, congenital adrenal hyperplasia, Barrett's syndrome)
Patients before or after neurosurgery
Require chemotherapy hydration
Severe liver disease
Patients who are likely to receive maintenance serum for less than 6 hours</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I15.8</hc_code>
      <hc_code>E87.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other secondary hypertension</hc_keyword>
      <hc_keyword>Hypo-osmolality and hyponatremia</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Normal saline maintenance fluid, 4cc/kg.h for first 10kg, 2cc/kg.h for second 10kg, and 2cc/kg.h for third and more 10kg. There is no specific brand to use and it will depend on Bahrami hospital's drugstore. Training sessions is not in our method. Administration time will depend on ICU admission period. The chemical formula is obvious according to drug's name and it is NaCl 0.9%.</i_keyword>
      <i_keyword>Control group: Half saline maintenance fluid, 4cc/kg.h for first 10kg, 2cc/kg.h for second 10kg, and 2cc/kg.h for third and more 10kg. There is no specific brand to use and it will depend on Bahrami hospital's drugstore. Training sessions is not in our method. Administration time will depend on ICU admission period. The chemical formula is obvious according to drug's name and it is NaCl 0.45%.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>ُBlood Sodium level. Timepoint: 6,24,48, and 72 hours. Method of measurement: Blood lab test, with the same kit for all patients.</prim_outcome>
      <prim_outcome>Blood pressure. Timepoint: Every hour. Method of measurement: Non-invasive blood pressure monitoring, with appropriate cuff size.</prim_outcome>
      <prim_outcome>Blood PH. Timepoint: hours 6، 24، 48 , 72. Method of measurement: Blood lab test, with the same kit for all patients.</prim_outcome>
      <prim_outcome>Blood bicarbonate level. Timepoint: hours 6، 24، 48 , 72. Method of measurement: Blood lab test, with the same kit for all patients.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-10-11</approval_date>
        <contact_name>Mohammad Eftekhari</contact_name>
        <contact_address>Keshavarz Blvd, Tehran university of medical science, school of medicine, Tehran, Iran. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
